GENB vs BRVE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
GENB · Generate Biomedicines$13.06 ▲ 3.90%
BRVE · Braveheart Bio$18.60 ▲ 6.80%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- GENB -6.0%
- BRVE -37.6%
Head to head
| Metric | GENB | BRVE |
|---|---|---|
| Price | $13.06 | $18.60 |
| Change today | ▲ 3.90% | ▲ 6.80% |
| Market cap | $1.68B | $1.67B |
| Return, 3 months | -11.3% | -32.4% |
| Return, year to date | – | – |
| Return, 1 year | – | – |
| P/E (TTM) | – | – |
| P/B | 3.7 | -17.5 |
| P/E percentile vs own 5y | 40th | 59th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -37.7% | – |
| Net profit growth (YoY) | -18.5% | -3,833.9% |
| Gross margin | – | – |
| Operating margin | -991.2% | – |
| Net margin | -1,014.5% | – |
| Return on equity | -58.9% | – |
| Analyst target vs. price | +99.1% | +143.3% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 46 | 39 |
| 30-day volatility | 93.8% | 78.6% |
| Max drawdown, 1 year | -40.7% | -41.9% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GENB is the largest of the group by market value.
- BRVE has been the calmest stock over the last 30 days.